Precipio achieved a 22% year-over-year revenue increase in Q2 2026, concluding the period with over $3 million in cash and a positive Adjusted EBITDA.
Quarterly revenue hits an all-time high as Precipio returns to positive Adjusted EBITDA and bolsters its cash reserves
Precipio, Inc. (NASDAQ:PRPO)
NEW HAVEN, CT, UNITED STATES, August 17, 2026 /EINPresswire.com/ — Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics firm, today disclosed its financial results for the second quarter ended June 30, 2026.
Precipio, Inc. is a B2i Digital Featured Company. A comprehensive company profile is available at: https://b2idigital.com/precipio-inc-1
Key financial performance indicators for the Company are listed below. For further details, refer to the Company’s Form 10-Q submitted today.
Revenue – $7.0M, compared to $6.7M in Q1-2026, and an increase of 22% YoY from $5.7M in Q2-2025. This figure consists of $6.1M in pathology revenue (up from $6.0M in Q1) and $0.9M in product revenue (up from $0.66M in Q1).
Adjusted EBITDA – $0.4M, versus $(0.2)M in Q1-2026. The shift was driven by a $0.3 million rise in revenues and a $0.2M reduction in stock-based compensation expense.
Cash flow – Cash generated by operations reached $0.7M in Q2-2026; the total cash increase was $0.5 million, culminating in a quarter-end cash balance above $3M, compared to $1.1M in Q2-2025.
“As we expected, Q2 operating results reflect a strong recovery and sustained momentum throughout the business, with client growth driving quarterly revenue beyond $7M for the first time in Company history. Product revenues rose 21% from the prior peak of $750K in Q4-2025, and cash increased to over $3M.” stated Ilan Danieli, CEO of Precipio. “We reached this cash level without any financing event, underscoring the power of our operations. We are pleased with our progress and believe we are well situated to keep building on this momentum.”
A deeper review of the Company’s Q2-2026 performance will be presented during the shareholder call on August 17th, 2026, at 5 PM ET. Management will discuss core business activities, followed by a moderated Q&A session.
EBITDA and Adjusted EBITDA Reconciliation and Explanation
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a non-GAAP financial metric frequently applied to assess operational performance and pre-tax profitability for growing companies such as ours. Management believes that Adjusted EBITDA offers investors a meaningful view of the Company’s financial condition, especially where non-cash amortization significantly affects profitability.
Our definition of Adjusted EBITDA modifies EBITDA by removing the non-cash costs of employee stock options as well as unusual non-operating income and expense. The table below provides a reconciliation of Net Income, EBITDA, and Adjusted EBITDA for the second quarters of 2026 and 2025:
EBITDA and Adjusted EBITDA Reconciliation ($ in millions, unaudited)
Net income/(loss) (GAAP): $(0.2) in Q2-2026 vs. $0.1 in Q2-2025
Adjustments to net income/(loss):
Interest expense, net: $0.0 vs. $0.0
Income taxes: $0.0 vs. $0.0
Depreciation: $0.0 vs. $0.1
Amortization of intangibles: $0.2 vs. $0.2
EBITDA (non-GAAP): $0.0 in Q2-2026 vs. $0.4 in Q2-2025
Further adjustments to EBITDA:
Stock-based compensation expense: $0.8 vs. $0.4
Other significant (income) expenses: $(0.4) vs. $(0.9)
Adjusted EBITDA (non-GAAP): $0.4 in Q2-2026 vs. $(0.1) in Q2-2025
About Precipio
Precipio is a healthcare biotechnology company specializing in cancer diagnostics. Its mission is to tackle the widespread problem of cancer misdiagnoses by creating diagnostic products and services. These offerings deliver enhanced accuracy, improved laboratory workflows, and ultimately better patient outcomes while lowering healthcare costs. Precipio develops innovative technologies in its own lab, where it designs, tests, validates, and clinically applies these products to improve diagnostic results. The company then commercializes these technologies as proprietary products serving the global laboratory community, thereby expanding Precipio’s reach to eliminate misdiagnosis.
Availability of Other Information About Precipio
For further details, please visit the Precipio website at https://www.precipiodx.com/ or follow Precipio on X (formerly Twitter) (@PrecipioDx), LinkedIn (Precipio), and Facebook. Investors and other parties should note that the company communicates with investors and the public through its corporate website (https://www.precipiodx.com), which includes but is not limited to company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X and LinkedIn. Information posted on the company’s website or on X or LinkedIn may be deemed material. Therefore, investors, media, and others are encouraged to regularly review such content. The contents of the company’s website or social media channels are not considered incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains “forward-looking statements” as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this release that are not historical facts should be regarded as forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing.
Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, adjusted EBITDA, plans, objectives, expectations, growth or profitability and our potential to reach financial independence are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Inquiries:
investors@precipiodx.com
+1-203-787-7888 Ext. 523
Media Contact:
David Shapiro
B2i Digital, Inc.
+1 212-579-4844
david@b2idigital.com
Visit us on social media:
LinkedIn
Bluesky
Instagram
Facebook
YouTube
TikTok
X
Other
